DrugBaron
FEBRUARY 16, 2024
“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. It is now more than a decade since Francesco De Rubertis, together with Kevin Johnson and Michele Olier, coined the term “asset-centric” investing to describe the approach to portfolio creation that still underpins the strategy at Medicxi.
Forbes: Drug Truths
MARCH 6, 2024
There is another aspect of this provision of the IRA that is starting to be felt – "the small molecule penalty"
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ASPET
SEPTEMBER 20, 2024
Post-traumatic stress disorder (PTSD) is caused by exposure to a traumatic or stressful event. Symptoms related to this disorder include persistent re-experiencing of memories and fear generalization. Current pharmacological treatments for PTSD are insufficient, with fewer than 30% of patients reporting symptom remission. This study aims to determine the efficacy of acute ( R,S) ketamine and chronic fluoxetine (FLX) in reducing fear memory and fear generalization.
Chemical Biology and Drug Design
FEBRUARY 15, 2024
Role of serotonin, dopamine, and norepinephrine in neural functions and symptoms involved during their altered levels. Abstract Depression is not similar to daily mood fluctuations and temporary emotional responses to day-to-day activities. Depression is not a passing problem; it is an ongoing problem. It deals with different episodes consisting of several symptoms that last for at least 2 weeks.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Broad Institute
OCTOBER 29, 2024
New drug triggers rapid cell death in cancer models By Karen Zusi-Tran October 29, 2024 Breadcrumb Home New drug triggers rapid cell death in cancer models BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models. By Karen Zusi-Tran October 29, 2024 Credit: National Cancer Institute Human cells with acute myelocytic leukemia (AML) in the pericardial fluid.
Drug Target Review
DECEMBER 20, 2024
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Concerns surrounding data security, the complexity of AI systems, and the rigorous regulatory frameworks in this field have caused the pharmaceutical industry to approach these technologies with caution. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
BioPharma Drive: Drug Pricing
OCTOBER 4, 2024
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.
Nvidia Developer: Drug Discovery
OCTOBER 2, 2024
A groundbreaking drug-repurposing AI model could bring new hope to doctors and patients trying to treat diseases with limited or no existing treatment options. A groundbreaking drug-repurposing AI model could bring new hope to doctors and patients trying to treat diseases with limited or no existing treatment options. Called TxGNN, this zero-shot tool helps doctors find new uses for existing drugs for conditions that might otherwise go untreated.
Drugs.com
MARCH 6, 2024
WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead. The FDA urged folks to throw away and not buy the following brands of.
Practical Cheminformatics
OCTOBER 8, 2024
“Pay no attention to the man behind the curtain” - The Wizard of Oz Introduction Recently, a few groups have proposed general-purpose large language models (LLMs) like ChatGPT , Claude , and Gemini as tools for generating molecules. This idea is appealing because it doesn't require specialized software or domain-specific model training. One can provide the LLM with a relatively simple prompt like the one below, and it will respond with a list of SMILES strings.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
DrugBaron
JANUARY 31, 2024
This month’s announcement that Alphabet’s Isomorphic Labs, led by the talented and charismatic Deepmind co-founder Demis Hassabis, had inked discovery collaboration deals with both Lilly and Novartis was just the latest indication that AI-enabled pharma R&D was ready for the big time. Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not ju
Forbes: Drug Truths
MARCH 4, 2024
The thought that all drugs arise from government funded research is a fallacy.
ASPET
SEPTEMBER 16, 2024
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that develops following exposure to a traumatic event. Individuals with this condition experience numerous physiological and behavioral alterations, including intrusive memories, avoidance of trauma-related stimuli, heightened anxiety, hypervigilance, impaired cognition, elevated resting heart rate and blood pressure, and altered neuroendocrine function, to name a few.
Chemical Biology and Drug Design
JANUARY 4, 2024
Curcumin activates ATF6-regulated endoplasmic reticulum (ER) stress, promotes ATF6 nuclear translocation, activates Chop/Bax/Bcl-2/Caspase-3 apoptosis pathway, and promotes apoptosis of CRC cells. Abstract Colorectal cancer (CRC) is the main cause of cancer-associated death. Herein, we treated SW620 and HT-29 CRC cells with different curcumin concentrations, followed by treatment with the half maximal inhibitory concentration (IC50) curcumin/endoplasmic reticulum stress (ERS) inhibitor 4-phenyl
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Broad Institute
JULY 10, 2024
Prime editing efficiently corrects cystic fibrosis mutation in human lung cells By Allessandra DiCorato July 10, 2024 Breadcrumb Home Prime editing efficiently corrects cystic fibrosis mutation in human lung cells The approach targets the most common genetic cause of the disease and could enable a one-time treatment as effective as existing daily therapies.
Drug Target Review
JANUARY 8, 2024
What is “healthspan” and how does it relate to Life Bioscience’s mission? It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. If we take into consideration the timeframe of our lives, our “healthspan” is defined as the number of healthy years we live, which is different than our lifespan, the number of years of life.
Science Daily: Pharmacology News
DECEMBER 25, 2024
Scientists have developed an innovative therapeutic platform by mimicking the intricate structures of viruses using artificial intelligence (AI).
BioPharma Drive: Drug Pricing
OCTOBER 16, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Nvidia Developer: Drug Discovery
DECEMBER 3, 2024
Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range. Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders.
Codon
SEPTEMBER 29, 2024
2024 Statistical models of organisms have existed for decades. The earliest ones relied on simple linear regression and attempted to correlate genetic variations with observable traits or disease risks — such as drug metabolization rates or cancer susceptibility. As computational power increased and machine learning techniques advanced, the models’ sophistication grew.
Drugs.com
DECEMBER 23, 2024
December 23, 2024 -- Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic.
Practical Cheminformatics
JANUARY 8, 2024
Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Some areas, like large language models, are new, and most of the work is at the proof-of-concept stage. Others, like active learning, are more mature, and several groups are starting to explore nuances of the methods. Here’s the structure of Part II. 4.
Forbes: Drug Truths
APRIL 11, 2024
Only biopharma could have combated Covid-19; no other industry has the capacity to do so. When the world was in crisis, this industry responded. If need be, it will again, despite the financial consequences.
ASPET
JULY 26, 2024
Cannabis and its products have been used for centuries for both medicinal and recreational purposes. The recent widespread legalization of cannabis has vastly expanded its use in the United States across all demographics except for adolescents. Meanwhile decades of research have advanced our knowledge of cannabis pharmacology and particularly of the endocannabinoid system with which the components of cannabis interact.
keypoint
DECEMBER 20, 2024
Meet the Keystone Symposia Fellows Class of 2025, a stellar group of post-doctoral fellows and early-career scientists who will take part in this prestigious mentorship program.
Broad Institute
JUNE 14, 2024
Some CRISPR screens may be missing cancer drug targets By Allessandra DiCorato June 14, 2024 Breadcrumb Home Some CRISPR screens may be missing cancer drug targets Current CRISPR guides don’t work equally well in cells from people of all ancestries, which could lead to false negative results. By Allessandra DiCorato June 14, 2024 Credit: Ricardo Job-Reese, Broad Communications CRISPR/Cas9 gene editing has made possible a multitude of biomedical experiments including studies that systematically t
Drug Target Review
DECEMBER 9, 2024
The 2024 Nobel Prize in Chemistry was awarded to Demis Hassabis and John Jumper from Google DeepMind for developing AlphaFold2, and to David Baker from the University of Washington for his work in computational protein design. These innovations have revolutionised the understanding of protein structures using artificial intelligence. Before AlphaFold, determining 3D protein structures was complex and time-consuming, and often required the use of experimental methods like X-ray crystallography an
Science Daily: Pharmacology News
SEPTEMBER 17, 2024
Consuming moderate amounts of coffee and caffeine regularly may offer a protective effect against developing multiple cardiometabolic diseases, including type 2 diabetes, coronary heart disease and stroke, according to new research.
BioPharma Drive: Drug Pricing
OCTOBER 22, 2024
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
LifeSciVC
JANUARY 16, 2024
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Just in time for new years’ reflections and resolutions, this year’s JPM felt like a refreshing burst of enthusiasm for a sector that has seen its challenges in 2022 and 2023 but also some green shoots. 2023 was a stellar year for M&A, comeback stories, burgeoning “hot” spaces, and for re-learning the basics of belt-tightening and careful capital allocation.
Codon
JULY 14, 2024
Dr. Keith Neeves gives a history of blood transfusions and explains why it will be difficult to scale up the creation of synthetic blood for Issue 03 of Asimov Press. We are mostly blood. Of the 36 trillion cells in the human body, 32 trillion are blood cells. These blood cells synchronize the delivery of oxygen to every tissue in your body, fight pathogens, and heal wounds.
Drugs.com
NOVEMBER 18, 2024
MONDAY, Nov. 18, 2024 -- Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows.The two drugs are metformin, one of the most widely used diabetes medications, and the.
Practical Cheminformatics
JANUARY 16, 2024
Following up on Part I and Part II, the third post in this series is a collection of review articles published in 2023 that I found helpful.
Expert insights. Personalized for you.
355 
Let's personalize your content